Global Pharmaceutical contract research organization (CRO) market will reach $45.0 billion by 2030, growing by 9.8% annually over 2021-2030, driven by the increasing incidence of disease, rising healthcare expenditures, increasing dependence on contract research organizations due to improved efficiency and productivity. 

Highlighted with 118 tables and 80 figures, this 194-page report “Global Pharmaceutical Contract Research Organization (CRO) Market 2021-2030 by Service, Therapeutic Application, End User, and Region: Trend, Forecast and Growth Opportunity” is based on comprehensive research of the entire global pharmaceutical contract research organization (CRO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2030 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure 

• Growth Drivers 

• Restraints and Challenges

• Emerging Product Trends & Market Opportunities

• Porter’s Fiver Forces

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global pharmaceutical contract research organization (CRO) market in every aspect of the classification from perspectives of Service, Therapeutic Application, End User, and Region. 

Based on Service, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section. 

• CRO for Pre-clinical Development

• CRO for Phase I Trials

• CRO for Phase II Trials

• CRO for Phase III Trials

• CRO for Phase IV Trials

• Laboratory Services

• Consulting Services

• Data Management Services 

Based on Therapeutic Application, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section. 

• Infectious Diseases

• Oncology

• Metabolic Disorders

• Cardiovascular Disorders

• Central Nervous System

• Respiratory Disorders

• Gastrointestinal Disorders

• Other Therapeutic Applications

By End User, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section. 

• Pharmaceutical & Biopharmaceutical Companies

• Medical Device Companies

• Academic Institutes

Geographically, the following regions together with the listed national/local markets are fully investigated:

• North America (U.S., Canada, and Mexico)

• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)

• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

• South America (Brazil, Chile, Argentina, Rest of South America)

• MEA (UAE, Saudi Arabia, South Africa, Other Nations)

For each aforementioned region and country, detailed analysis and data for annual revenue ($ bn) are available for 2021-2030. The breakdown of all regional markets by country and split of key national markets by Service, Therapeutic Application, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Selected Key Players: 

Charles River Laboratories

CMIC Co. Ltd

Covance Inc.

Hangzhou Tigermed Consulting Co., Ltd.

ICON Plc

IQVIA Holdings Inc.

LSK Global Pharma Service Co., Ltd.

Novotech Pty Ltd

PAREXEL International Corporation

Pharmaceutical Product Development LLC (PPD)

PRA Health Sciences Inc.

Quanticate Ltd

Samsung Bioepis Co., Ltd.

SGS SA (SGS Life Sciences)

Syneos Health Inc.

WuXi AppTec Inc. 

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)